About us

History

VelaLabs was founded as ​“Vela phar­mazeutische Entwick­lung und Labo­r­an­a­lytik GmbH” as a manage­ment buy out end of 2006 and took over analytic and infra­struc­ture of the former Novartis spin off Ingeneon.

From the begin­ning it has special­ized in the char­ac­ter­i­za­tion of biologics and early real­ized the poten­tial of biosimilars.

In 2007, VelaLabs was GMP-certi­fied and imple­mented GCLP rules in 2009 to be able to conduct the sample analysis of clin­ical studies according to rele­vant guidelines.

Further mile­stones:

• 2011: first batch release testing of clin­ical material
• 2014: first market mate­rial (G‑CSF)
• 2019: regis­tered at the FDA
• 2020: GLP certi­fi­ca­tion
• 2020: Acquis­tion of LABH (Labor für Betrieb­shy­giene), building a new clean room for sterility testing under GMP conditions

In 2016 Tentamus group – inter­na­tion­ally posi­tioned with more than 90 labo­ra­to­ries in 23 coun­tries – acquired VelaLabs, perfectly fitting into the group’s ​‘closer-to-the-customer’ strategy based on local labs covering the full service port­folio along the chain of custody.

Until today VelaLabs intro­duced further analyt­ical services such as ECL tech­nology (MesoScaleDis­covery), being part of a PBMC network and a cell based assay coop­er­a­tion, as well as latest equip­ment for SPR testing, and multi label reader with qual­i­fied eval­u­a­tion soft­ware.

The team grew to over 80 employees until 2022.

Our vision

Share our vision of mean­ingful analytics to support medica­tion development.

Inno­va­tion, flex­i­bility, and perfor­mance of our analytics ensure product safety and it is our contri­bu­tion to a healthier life.